var data={"title":"Cefaclor: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefaclor: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5833?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefaclor-drug-information\" class=\"drug drug_general\">see &quot;Cefaclor: Drug information&quot;</a> and <a href=\"topic.htm?path=cefaclor-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefaclor: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146901\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cefaclor;</li>\n      <li>Ceclor;</li>\n      <li>Novo-Cefaclor;</li>\n      <li>Nu-Cefaclor;</li>\n      <li>PMS-Cefaclor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045856\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045848\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefaclor-drug-information\" class=\"drug drug_general\">see &quot;Cefaclor: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Mild to moderate infection: Infants, Children, and Adolescents: Oral, immediate release: 20 to 40 mg/kg/day divided every 8 to 12 hours. Maximum daily dose: 1,500 mg/<b>day</b> (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchitis:</b> Adolescents &ge;16 years: Extended release tablet: <b>Note:</b> An extended release tablet dose of 500 mg twice daily is clinically equivalent to an immediate release capsule dose of 250 mg 3 times daily; an extended release tablet dose of 500 mg twice daily is <b>NOT</b> clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute bacterial exacerbations of chronic bronchitis: Oral: Extended release: 500 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary bacterial infection of acute bronchitis: Oral: Extended release: 500 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower respiratory tract infections:</b> Infants, Children, and Adolescents: Oral immediate release: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/<b>day</b>. If beta-hemolytic streptococcus/<i>S. pyogenes</i> suspected, treat for at least 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media:</b> Infants, Children, and Adolescents: Oral immediate release: 40 mg/kg/day divided every 8 to 12 hours (oral suspension) or every 8 hours (capsule); maximum daily dose: 1,000 mg/<b>day</b>. If beta-hemolytic streptococcus/<i>S. pyogenes</i> suspected, treat for at least 10 days. <b>Note:</b> Cefaclor is not a recommended treatment option in the AAP guidelines (Lieberthal 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis:</b> Infants, Children, and Adolescents: Oral immediate release: 20 mg/kg/day divided every 8 to 12 hours (oral suspension) or every 8 hours (capsule); maximum daily dose: 1,000 mg/<b>day</b>. If beta-hemolytic streptococcus/<i>S. pyogenes</i> confirmed, treat for at least 10 days. <b>Note:</b> Cefaclor is not a recommended treatment option in the IDSA guidelines and is not considered preferred by the AHA due to its broad spectrum (AHA [Gerber 2009], IDSA [Shulman 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, uncomplicated:</b> Infants, Children, and Adolescents: Oral: Immediate release: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/<b>day</b>. If due to beta-hemolytic streptococcus/<i>S. pyogenes</i>, treat for at least 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b> Infants, Children, and Adolescents: Oral: Immediate release: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>General dosing, susceptible infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, immediate release: 250 to 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, extended release: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, half-life is increased in anuric patients; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternative recommendations (Aronoff 2007): Dosing based on usual dose of 20 to 40 mg/kg/day in divided doses every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: Oral, immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End-stage renal disease (ERD) on intermittent hemodialysis (IHD) (supplemental dose posthemodialysis needed): Administer 50% of the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: Administer 50% of the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Oral, immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to severe impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Supplement with 250 to 500 mg after dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: Administer 250 to 500 mg every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Hemodialysis shortens half-life by 25% to 35%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderately dialyzable (20% to 50%) (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146876\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146860\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045860\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablets: Do not chew, crush, or split; administer with or within 1 hour of food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146895\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).  Refrigerate suspension after reconstitution and discard after 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045859\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule and suspension: Treatment of otitis media, lower respiratory tract infections, pharyngitis/tonsillitis, urinary tract infections, and skin/skin structure infections (FDA approved in ages &ge;1 month and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Treatment of acute bacterial exacerbations of chronic bronchitis, secondary bacterial infections of acute bronchitis (FDA approved in ages &ge;16 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146951\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefaclor may be confused with cephalexin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146949\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash (includes erythematous rash, maculopapular rash, or morbilliform rash) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Vaginitis, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Agitation, agranulocytosis, anaphylaxis, angioedema, aplastic anemia, arthralgia, cholestatic jaundice, confusion, dizziness, drowsiness, hallucination, hemolytic anemia, hepatitis, hyperactivity, insomnia, interstitial nephritis, irritability, nausea, nervousness, neutropenia, paresthesia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146882\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefaclor, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146864\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Anaphylactic reactions have occurred.  If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and treatment (eg, epinephrine, antihistamines, and/or corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; <i>H. influenzae</i> infections: Beta-lactamase-negative, ampicillin-resistant (BLNAR) strains of <i>H. influenzae</i> should be considered resistant to cefaclor. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extended-release tablet:  An extended-release tablet dose of 500 mg twice daily is clinically equivalent to an immediate-release capsule dose of 250 mg 3 times daily; an extended-release tablet dose of 500 mg twice daily is <b>NOT</b> clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855318\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause serum sickness-like reaction (estimated incidence ranges from 0.024% to 0.2% per drug course); majority of reactions have occurred in children &lt;5 years of age with symptoms of fever, rash, erythema multiforme, and arthralgia, often occurring during the second or third exposure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298983\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146869\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13122&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146896\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">The bioavailability of cefaclor extended-release tablets is decreased 23% and the maximum concentration is decreased 67% when taken on an empty stomach. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46099040\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5953385\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045855\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor CBC and stool frequency periodically</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146863\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146881\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed; acid stable </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into tissues and fluids including bone, pleural and synovial fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 25% (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.6 to 0.9 hours; prolonged with renal impairment (2.3 to 2.8 hours in anuria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Capsules, oral suspension: 30 to 60 minutes; Extended-release tablets: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146884\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cefaclor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $59.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $116.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cefaclor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (150 mL): $630.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (150 mL): $630.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg/5 mL (100 mL): $630.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Cefaclor ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $2,139.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146887\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abaclor (BD);</li>\n      <li>Achlor (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ackfa (LK);</li>\n      <li>Aclor (AU);</li>\n      <li>Aczebri (PH);</li>\n      <li>Alclor (BD);</li>\n      <li>Alfatil (FR);</li>\n      <li>Alfatil LP (FR);</li>\n      <li>Bearclor (VN);</li>\n      <li>Beinuoke (CN);</li>\n      <li>Bioclocel (PH);</li>\n      <li>CEC (AT, BG, DO, ZA);</li>\n      <li>Cec (MX);</li>\n      <li>CEC 500 (DE);</li>\n      <li>Ceclobid (PH);</li>\n      <li>Ceclodyne (RO);</li>\n      <li>Ceclor (AE, AT, AU, BB, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, EC, EG, ES, ET, GH, GM, GN, GR, GY, HK, HN, HU, JM, JO, KE, KR, LB, LR, MA, ML, MR, MU, MW, MX, NE, NG, NL, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, VE, ZM, ZW);</li>\n      <li>Ceclor AF (PE);</li>\n      <li>Ceclor CD (AU);</li>\n      <li>Ceclor DS (PH);</li>\n      <li>Ceclor MR (BF, BH, BJ, CI, CY, ET, GH, GM, GN, HK, KE, KW, LB, LR, MA, ML, MR, MU, MW, NE, NG, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ceclor PDR (CY);</li>\n      <li>Ceclor Retard (CH);</li>\n      <li>Ceclor SR (NZ);</li>\n      <li>Cecrun (KR);</li>\n      <li>Cefabac (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Cefacle (KR);</li>\n      <li>Cefaloc (PH);</li>\n      <li>Cefclor (TH);</li>\n      <li>Cefkor (AU);</li>\n      <li>Ceflacid (MX);</li>\n      <li>Cefmed (PH);</li>\n      <li>Cektin (KR);</li>\n      <li>Celormed (VN);</li>\n      <li>Cephlor (AE, BH, CY, EG, IL, IQ, IR, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Ceracl (KR);</li>\n      <li>Cero (TW);</li>\n      <li>Cevacl (KR);</li>\n      <li>Cleancef (SG, VN);</li>\n      <li>Clex (KR);</li>\n      <li>Clocef (BD);</li>\n      <li>Cloracef (ID, JO, QA);</li>\n      <li>Cloracef MR (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Clorcef (PH);</li>\n      <li>Clorotir (NZ);</li>\n      <li>Distaclor (CO, GB, IE, MY, SG, TH);</li>\n      <li>Doccefaclo (BE);</li>\n      <li>Dorocor (VN);</li>\n      <li>Efaclor (MY);</li>\n      <li>Eurocefix (MT);</li>\n      <li>Forbatec (AE, BH, CY, EG, IL, IQ, IR, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Forifek (ID);</li>\n      <li>Forticef (JO);</li>\n      <li>Haxifal (FR);</li>\n      <li>Karlor (AU);</li>\n      <li>Karlor CD (AU);</li>\n      <li>Kefaclor (TZ);</li>\n      <li>Keflor (AU, IN);</li>\n      <li>Keflor CD (AU);</li>\n      <li>Kefolor (FI);</li>\n      <li>Keftid (GB);</li>\n      <li>Kemocin (KR);</li>\n      <li>Kerfenmycin (TW);</li>\n      <li>Locef (NZ);</li>\n      <li>Lorcef (PH);</li>\n      <li>Medacef (AE, BH, KW, QA, SA);</li>\n      <li>Medoclor (BG, TR);</li>\n      <li>Metiny (VN);</li>\n      <li>Miclor (KR);</li>\n      <li>Midocef (JO);</li>\n      <li>Ozcef (AU);</li>\n      <li>Panacef (IT);</li>\n      <li>Panoral (DE);</li>\n      <li>Panoral Forte (DE);</li>\n      <li>Pharmaclor (AE, BH, CY, EG, IL, IQ, IR, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Pinaclor (IE);</li>\n      <li>Qualiceclor (HK);</li>\n      <li>Qualiphor (HK);</li>\n      <li>Ranclor (MX);</li>\n      <li>Sefaclor (MY);</li>\n      <li>Seporin (KR);</li>\n      <li>Serviclor (MX);</li>\n      <li>Sifaclor (TH);</li>\n      <li>Soclor (ID);</li>\n      <li>Soficlor (HK, MY);</li>\n      <li>Surecef (PH);</li>\n      <li>Swiflor (TW);</li>\n      <li>U-Clor (TW);</li>\n      <li>Vefarol (PH);</li>\n      <li>Vercaf (ZW);</li>\n      <li>Vercef (AE, BF, BH, BJ, CI, ET, GH, GM, GN, KE, KW, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Versef (PH);</li>\n      <li>Wonclor (KR);</li>\n      <li>Xelent (PH);</li>\n      <li>Xeztron (PH);</li>\n      <li>Zaike (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boguniewicz M and Leung DYM, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):221-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/7761188/pubmed\" target=\"_blank\" id=\"7761188\">7761188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefaclor capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefaclor extended-release tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefaclor oral suspension [prescribing information]. Charlotte, NC: FSC Laboratories, INC; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/19246689 /pubmed\" target=\"_blank\" id=\"19246689 \">19246689 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-999.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012; 15;55(10):1279-1282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/23091044 /pubmed\" target=\"_blank\" id=\"23091044 \">23091044 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13122 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146901\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045856\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045848\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146876\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F146860\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045860\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F146895\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045859\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F146951\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146949\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146882\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146864\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855318\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298983\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146869\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F146896\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F46099040\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5953385\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045855\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146863\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F146881\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F146884\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146887\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13122|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefaclor-drug-information\" class=\"drug drug_general\">Cefaclor: Drug information</a></li><li><a href=\"topic.htm?path=cefaclor-patient-drug-information\" class=\"drug drug_patient\">Cefaclor: Patient drug information</a></li></ul></div></div>","javascript":null}